CASIN

CASIN (CAS: 425399-05-9) is a potent and selective small-molecule inhibitor of the Rho family GTPase Cdc42, widely used in stem cell biology, oncology, and cell signaling research. Featuring a unique tetrahydrocarbazole-based molecular architecture with an aminoethanol side chain, it offers a well-defined mechanism of action that directly inhibits Cdc42 activation (IC₅₀ = 2 µM) without competing for GTP binding. Its well-established specificity for Cdc42 over other Rho GTPases, reliable synthetic accessibility, and demonstrated efficacy in reversing age-related phenotypes make it a dependable standard for drug discovery, chemical biology, and molecular pharmacology research. Its primary applications are outlined below:

1. Stem Cell Biology & Aging Research

Hematopoietic Stem Cell (HSC) Rejuvenation
CASIN is most prominently employed as a pharmacological tool to reverse the functional decline of aged hematopoietic stem cells. By reducing elevated levels of active Cdc42 in aged primitive HSCs to youthful levels, it restores cell polarity, improves engraftment capacity, and rebalances lineage reconstitution in transplantation models . Researchers utilize CASIN ex vivo (at 5 µM) to rejuvenate aged HSCs prior to transplantation, demonstrating functional restoration comparable to young HSCs .

HSC Mobilization Studies
The compound has been validated in vivo as an effective mobilizer of hematopoietic stem and progenitor cells (HSPCs). A single intraperitoneal dose of CASIN (5 mg/kg) in mice results in an approximately 6-fold increase in circulating progenitor cell activity, making it a valuable tool for studying HSC mobilization pathways and optimizing transplantation protocols .

Epigenetic & Polarity Studies
CASIN treatment increases histone H4K16 acetylation in aged HSCs and reverses aging-related polarity phenotypes . Researchers employ it to investigate the molecular mechanisms linking Cdc42 activity to epigenetic changes and stem cell aging.

2. Oncology & Cancer Research

Targeting Cancer Stem Cells
CASIN facilitates the eradication of leukemia stem cells (LSCs) when combined with chemotherapeutic regimens (e.g., AraC + QC) and prolongs survival in xenografted mouse models, without affecting long-term normal human hematopoiesis . This positions CASIN as a valuable probe for studying cancer stem cell quiescence and chemoresistance.

Cancer Cell Proliferation & Migration Studies
In multiple myeloma (MM) and other cancer cell lines, CASIN inhibits cell growth and sensitizes cells to conventional chemotherapeutics like melphalan and bortezomib . Its ability to disrupt Cdc42-dependent cytoskeletal dynamics is used to study cancer cell invasion, metastasis, and survival pathways.

Selectivity for Mechanistic Studies
Unlike cross-reactive inhibitors such as ML141 and AZA1 that also target Rac1 or RhoA, CASIN is reported as a Cdc42 activity-specific inhibitor. This superior selectivity makes it the preferred tool for experiments requiring clean, on-target dissection of Cdc42 function in cancer biology .

3. Cell Signaling & Cytoskeletal Research

Cdc42 Activation & Downstream Pathway Mapping
CASIN directly inhibits the activation of Cdc42 by its guanine nucleotide exchange factor (GEF) Intersectin-1, blocking the transition from inactive (GDP-bound) to active (GTP-bound) state . Researchers employ it to study downstream effectors such as PAK1/2, and to dissect Cdc42-mediated pathways regulating actin organization, cell polarity, and cell-cell adhesion .

Platelet Activation & Thrombosis Studies
In human platelets, CASIN (10 µM) completely blocks collagen-induced Cdc42-GTP formation and downstream PAK phosphorylation . It serves as a key pharmacological tool in hemostasis research to validate Cdc42 as a therapeutic target for preventing pathological thrombosis.

Chemical Probe for Target Validation
As a well-characterized chemical probe with an inactive structural analog (Pirl7) available as a negative control, CASIN is employed in target validation workflows. The head-to-head comparison with Pirl7 provides stringent evidence for on-target activity in cellular assays .

4. Drug Discovery & Preclinical Development

Lead Optimization & SAR Studies
The tetrahydrocarbazole scaffold of CASIN serves as a starting point for medicinal chemistry optimization. Researchers modify its structure to improve potency, selectivity, and pharmacokinetic properties, with the goal of developing clinical candidates for aging-related diseases, cancer, and thrombotic disorders.

Pharmacological Benchmarking
CASIN is widely used as a positive control and benchmark compound in high-throughput screening campaigns targeting Cdc42 or related Rho GTPases. Its well-defined potency (IC₅₀ = 2 µM) and established in vivo efficacy provide a reliable reference for validating new inhibitors .

Preclinical Efficacy Models
The compound is utilized in murine models to evaluate the therapeutic potential of Cdc42 inhibition in diverse disease contexts, including hematopoietic disorders, thrombosis, and inflammatory conditions.

5. Handling & Storage

Storage Conditions
Store powder at –20°C (stable for up to 3 years) or 4°C (up to 2 years) in tightly sealed, light-protected containers. Solutions in DMSO should be stored at –80°C (up to 6 months) or –20°C (up to 1 month) . Protect from moisture and strong oxidizing agents.

Solubility & Preparation
Soluble in DMSO (≥30–100 mg/mL) and ethanol (up to 50 mM); insoluble in water . For biological assays, prepare stock solutions in DMSO and dilute with aqueous buffers. Note that stock solutions should be aliquoted to avoid repeated freeze-thaw cycles.

Chemical Stability Considerations
The compound is stable under recommended storage conditions. Avoid prolonged exposure to light and air to prevent degradation.

Intended Use
This product is intended for research and laboratory use only. It is not approved for human therapeutic use, clinical diagnostics, or food applications. Standard laboratory safety practices (chemical fume hood, gloves, eye protection) should be followed during handling.

Summary

The value of CASIN (CAS: 425399-05-9) lies in its unique combination of selective Cdc42 inhibition, validated in vivo efficacy, and demonstrated ability to reverse aging-related stem cell phenotypes. Its applications span from stem cell rejuvenation and cancer stem cell eradication (as a chemical probe and lead compound) to cell signaling (as a tool for dissecting Cdc42 pathways) and preclinical drug discovery (as a benchmark for inhibitor development). Its well-defined mechanism of action, availability of an inactive control analog (Pirl7), and proven utility in both in vitro and in vivo models make it an indispensable standard for stem cell biology, oncology research, and molecular pharmacology worldwide.

For more information, please contact: selina@coreychem.com